New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access the report

›ETF Issuers›T. Rowe Price›TDNA

TDNA

T. Rowe Price Biotech ETF

Active ETF Equity

Not rated

The TDNA Exchange Traded Fund (ETF) is provided by T. Rowe Price. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.

$24.89

-$0.28 (-1.11%) 3 days ago

1:30 PM 10/30/26 Closed

1D price range

$24.72$24.89

52W price range

$22.72$25.68

YTD Perf.

+0.65%

YTD Flows

Annualized volatility

Fund AuM

€9.6M

Share class AuM

€9.6M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US87283Q6109

TER

0.55%

Inception date

9/16/2026

Issuer

T. Rowe Price

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
PTH Invesco DWA Healthcare Momentum ETF	+2.10%
XBI State Street SPDR S&P Biotech ETF	+4.26%
BBP Virtus LifeSci Biotech Products ETF	+2.00%
CURE Global X S&P Biotech ETF	+3.63%
ARKG ARK Genomic Revolution ETF	+6.73%
AAKG ARK Genomic Revolution UCITS ETF	+14.73%
XHE State Street SPDR S&P Health Care Equipment ETF	-1.94%
FMED Fidelity Disruptive Medicine ETF	+2.78%
XPH State Street SPDR S&P Pharmaceuticals ETF	+3.26%
HELX Franklin Genomic Advancements ETF	+5.34%
SBIO ALPS Medical Breakthroughs ETF	+2.96%
PSCH Invesco S&P SmallCap Health Care ETF	+3.24%
EKG First Trust Nasdaq Lux Digital Health Solutions ETF	+4.72%
XHS State Street SPDR S&P Health Care Services ETF	+1.24%
BBC Virtus LifeSci Biotech Clinical Trials ETF	+4.43%

API

PerformanceSep 16, 2026 - Oct 29, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 09/30/26

Healthcare

98.50%

Unavailable

1.50%

Latest TDNA news

No content available for this fund

FAQ about TDNA

TDNA is an actively managed ETF. This ETF provides exposure to Other Biotechnology Equities.

TDNA carries a total expense ratio (TER) of 0.55%.

TDNA was introduced to the market on September 16, 2026.

T. Rowe Price Biotech ETF, TDNA, is provided by T. Rowe Price. Learn more about T. Rowe Price here.

TDNA oversees €9.6M in assets as of October 29, 2026.

TDNA follows a distributing dividend policy, meaning it pays out income to investors.

As of September 30, 2026, TDNA has significant geographic allocations in USA, Netherlands and Ireland.

As of September 30, 2026, TDNA focuses largely on Healthcare.

As of September 30, 2026, TDNA holds 86 positions in its portfolio, with 37.16% of assets concentrated in its top 15 holdings.

As of September 30, 2026, TDNA top three holdings include argenx SE, Kymera Therapeutics, Inc. and Kodiak Sciences, Inc..

The base currency of TDNA is USD.

Top 10 holdings

Data as of 09/30/26

argenx SE

5.41%

Kymera Therapeutics, Inc.

4.04%

Kodiak Sciences, Inc.

2.68%

Insmed, Inc.

2.59%

Natera, Inc.

2.41%

Revolution Medicines, Inc.

2.37%

Vertex Pharmaceuticals, Inc.

2.25%

United Therapeutics Corp.

2.20%

Alnylam Pharmaceuticals, Inc.

1.98%

Dianthus Therapeutics, Inc.

1.91%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

T. Rowe Price Biotech ETF

FAQ about TDNA

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US